Indian pharmaceutical company Dr. Reddy’s Laboratories has announced that the company is open to producing Pfizer’s Covid-19 antiviral pill. Dr. Reddy’s is one among the Indian firms that have obtained licenses to manufacture Merck’s Covid-19 pill, molnupiravir. Merck has granted licenses to manufacturers in developing nations to ensure a quick supply of the drug across the globe, Reuters reported. Various firms hope that Pfizer will also provide licences to produce the pill. The UK and Bangladesh have authorised molnupiravir while Dr. Reddy’s awaits approval from the drug regulator in India.
Pfizer and BioNTech’s Covid-19 vaccine was shown to demonstrate a robust immune response in a study comparing four vaccines, Bloomberg reported. Furthermore, the study indicated that individuals who received Sinopharm‘s shot may be more vulnerable to a breakthrough infection. Findings showed that the Sinopharm and Sputnik V vaccines induced reduced concentrations of antibodies, while AstraZeneca’s vaccine stimulated intermediate levels. The causes for the disparities in immune responses between the four vaccines are not known yet.
Redhill Biopharma has enrolled the last subject in the Part A portion of a Phase II/III clinical trial of its new oral pill RHB-107 (upamostat) to treat individuals with symptomatic Covid-19 who do not require hospitalisation. Conducted in the US and South Africa, the two-part, randomised, multicentre, double-blind, placebo-controlled, parallel-group trial will assess the safety and efficacy of the antiviral drug. The company also submitted data modules for another oral Covid-19 drug candidate, opaganib, to regulatory agencies in the US, EU and UK, among others.